Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.
Motif Bio Conference Call and Webcast February 19, 2019 |
Motif BioSciences Enters into Amendment Agreement with Hercules Capital February 18, 2019 |
Motif Bio Receives Complete Response Letter from the FDA February 14, 2019 |
Motif Bio plc
201 Temple Chambers
3-7 Temple Avenue
London EC4Y 0DT
United Kingdom
Motif BioSciences Inc.
125 Park Avenue, 25th Floor
New York, NY 10017
United States
General:
info@motifbio.com
Investors:
ir@motifbio.com
© 2017 Motif Bio | Disclaimer & Terms of Use